Trials Sponsors Conditions Drugs Pricing

Conditions

Advanced Sleep Phase Syndrome (ASPS)Circadian Rhythm Disorders Circadian Rhythm Sleep Disorder Delayed Sleep Phase Syndrome Sleep Disorder Sleep Disorders, Circadian Rhythm Sleep Wake Disorders

Keywords

ASWPD, DSWPD, CRSWD, melatonin, circadian, circadian rhythm, biomarker

Outcome Measures

Primary Outcomes (3)

DLMO
dim light melatonin onset, the time at which melatonin levels in the saliva rise above 3pg/mL
Study Day 1
BodyTime
the time at which a series of rhythmic gene transcripts predict circadian phase
Study Day 1
PlasmaTime
the time at which a series of rhythmic proteins predict circadian phase
Study Day 1

Interventions

dim light melatonin onset (DLMO)Other

A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Healthy adults who meet ICSD-3 criteria for Advanced Sleep Wake Phase Disorder (ASWPD) or Delayed Sleep Wake Phase Disorder (DSWPD).

You may qualify if:

ICSD3 diagnosis of Advanced Sleep-Wake Phase Disorder or Delayed Sleep-Wake Phase Disorder

Sponsors & Collaborators

Stanford University
Othercollaborator
Brigham and Women's Hospital
Otherlead

Study Sites (1)

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Biospecimen

Retention: SAMPLES WITH DNA

Saliva samples will be collected and assayed for melatonin. Blood samples will be collected and assayed for rhythmic gene transcripts and rhythmic proteins. A blood sample will be collected for DNA analysis, including potential GWAS.

MeSH Terms

Conditions

Sleep Disorders, Circadian RhythmChronobiology DisordersSleep Wake Disorders

Condition Hierarchy (Ancestors)

Nervous System DiseasesDyssomniasOccupational DiseasesMental DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

Emmanuel Mignot, MD, PhD
Stanford University
PRINCIPAL INVESTIGATOR

Enrollment

50 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Co-Investigator

Study Record Dates

First Submitted

December 15, 2020

First Posted

December 30, 2020

Study Start

November 2, 2021

Actual (reported)

Validation of Circadian Biomarkers in Patients With Sleep Disorders

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations